| 词条 | Naptumomab estafenatox |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458269850 | image = | type = mab | mab_type = Fab | source = o | target = 5T4 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 676258-98-3 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 93T929W6LC | C=3255 | H=5025 | N=855 | O=1050 | S=18 | molecular_weight = 73.5 kg/mol }}Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2] Mechanism of actionChemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes. See also
References1. ^{{cite journal|pmid=19636016|year=2009|last1=Borghaei|first1=H|last2=Alpaugh|first2=K|last3=Hedlund|first3=G|last4=Forsberg|first4=G|last5=Langer|first5=C|last6=Rogatko|first6=A|last7=Hawkins|first7=R|last8=Dueland|first8=S|last9=Lassen|first9=U|title=Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer|volume=27|issue=25|pages=4116–23|doi=10.1200/JCO.2008.20.2515|pmc=2734423|journal=Journal of Clinical Oncology}} {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^ClinicalTrials.gov 3. ^WHO Drug Information 1 : Monoclonal antibodies for tumors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。